Prognosis Individualized: Survival predictions for WHO grade II and III gliomas with a machine learning-based web application

Mert Karabacak, Pemla Jagtiani, Alejandro Carrasquilla, Isabelle M. Germano, Konstantinos Margetis

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

WHO grade II and III gliomas demonstrate diverse biological behaviors resulting in variable survival outcomes. In the context of glioma prognosis, machine learning (ML) approaches could facilitate the navigation through the maze of factors influencing survival, aiding clinicians in generating more precise and personalized survival predictions. Here we report the utilization of ML models in predicting survival at 12, 24, 36, and 60 months following grade II and III glioma diagnosis. From the National Cancer Database, we analyze 10,001 WHO grade II and 11,456 grade III cranial gliomas. Using the area under the receiver operating characteristic (AUROC) values, we deploy the top-performing models in a web application for individualized predictions. SHapley Additive exPlanations (SHAP) enhance the interpretability of the models. Top-performing predictive models are the ones built with LightGBM and Random Forest algorithms. For grade II gliomas, the models yield AUROC values ranging from 0.813 to 0.896 for predicting mortality across different timeframes, and for grade III gliomas, the models yield AUROCs ranging from 0.855 to 0.878. ML models provide individualized survival forecasts for grade II and III glioma patients across multiple clinically relevant time points. The user-friendly web application represents a pioneering digital tool to potentially integrate predictive analytics into neuro-oncology clinical practice, to empower prognostication and personalize clinical decision-making.

Original languageEnglish
Article number200
Journalnpj Digital Medicine
Volume6
Issue number1
DOIs
StatePublished - Dec 2023

Fingerprint

Dive into the research topics of 'Prognosis Individualized: Survival predictions for WHO grade II and III gliomas with a machine learning-based web application'. Together they form a unique fingerprint.

Cite this